Today: 21 May 2026
D-Wave Quantum stock jumps 20% as quantum names rebound — what QBTS investors watch next week
8 February 2026
2 mins read

D-Wave Quantum stock jumps 20% as quantum names rebound — what QBTS investors watch next week

NEW YORK, Feb 8, 2026, 09:29 ET — The market isn’t open.

  • D-Wave Quantum jumped close to 20% by Friday’s close. Trading was heavy, with the stock rebounding sharply following a choppy run for speculative tech names.
  • Shares climbed as investors zeroed in on Big Tech’s AI spending plans, tracking a broader rally across Wall Street.
  • Focus turns to U.S. inflation data and jobs stats this week; traders are also scanning for fresh company filings.

D-Wave Quantum Inc jumped 20.4% on Friday, closing out at $20.72 as risk-heavy tech names caught a bid. The stock swung between $17.84 and $20.98, with about 38.7 million shares changing hands.

That surge stands out: D-Wave and the rest of the quantum-computing pack have been trading like high-beta bets—soaring as growth gets hot, dropping fast when risk appetite fades. After Friday’s pop, there’s still a long way down if sentiment turns sour.

Friday saw stocks rip higher, with the S&P 500 jumping 1.97% and the Nasdaq climbing 2.18%, fueled by chipmakers riding a surge in AI-related data-center bets. Amazon lagged, tumbling after flagging a significant rise in capex. “This trade has been volatile,” Baird’s Ross Mayfield pointed out. https://www.reuters.com/business/futures-s…

The company stayed quiet on Friday after the announcement. Quantum stocks picked up, with traders piling into tech risk again as the sector climbed.

After the late-January news, D-Wave investors latched onto the announcement as proof the company can land hefty commercial contracts—not just pilots. On Jan. 27, D-Wave said it had signed a $10 million “Quantum Computing as a Service” agreement, lasting two years and letting the customer tap into its quantum tech and services via the cloud. The buyer: a Fortune 100 company. https://ir.dwavequantum.com/news/news-deta…

Back then, CEO Alan Baratz called it “a significant milestone,” framing the deal as validation for the company’s enterprise strategy. That’s still coloring how traders look at bookings and contract sizes, even as quantum computing remains a far-off reality.

D-Wave’s financials have shifted sharply following the Quantum Circuits acquisition. The Jan. 20 filing spells it out: 10,430,444 shares traded, plus $250 million in cash changing hands, with potential tweaks still on the table.

The filing called it straight: merging the businesses could get messy, with costs rising and shares falling if promised synergies take too long to show up. The company flagged another risk, too — if performance disappoints, investors might dump the stock, a pattern familiar from previous forays into hardware.

Positioning throws another wrench into the mix. By mid-January, short interest stood at roughly 46.86 million shares—about 13% of the float, according to market data on Yahoo Finance. That kind of setup can amplify a squeeze or intensify a drop, depending on which way things break.

Stocks like QBTS, which move on rate speculation, could see action as traders track this week’s macro data. The Labor Department has pushed the January jobs report to Wednesday, and January CPI is now due Friday. Both releases were shuffled after a short government shutdown.

The Bureau of Labor Statistics will publish the CPI on Feb. 13 at 8:30 a.m. ET, per its calendar. If the number comes in hot, long-duration and cash-burning stocks are likely to feel the pressure again.

Monday opens with traders watching to see if Friday’s big quantum rebound can hold. Eyes are also on D-Wave—any new contracts or filings could shift the narrative, as the market continues to process last week’s jobs and inflation data.

Stock Market Today

  • Scotiabank Shares Showing 32% Undervaluation at C$108 Amid Strong Returns
    May 20, 2026, 10:05 PM EDT. Scotiabank (TSX:BNS) stock has rallied to around C$108.50, delivering a 59.4% return over the past year and nearly 79% over five years highlighting strong performance. Despite this, valuation models suggest substantial remaining upside. Simply Wall St's Excess Returns analysis estimates the bank's intrinsic value at approximately C$160 per share, indicating it is 32.2% undervalued compared to current prices. This model calculates excess returns by comparing the bank's return on equity to its cost of equity, reflecting efficient shareholder profit generation. Investors are closely watching key fundamentals including balance sheet resilience and dividend yield as Scotiabank navigates evolving interest rate environments. The stock's valuation score of 4 out of 6 suggests moderate confidence among analysts that price gains can continue.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Applied Digital stock surges 25% to $34.95 — what APLD investors are watching next week
Previous Story

Applied Digital stock surges 25% to $34.95 — what APLD investors are watching next week

Tencent stock price: WeChat AI “red packet” fight shadows Monday open after HK$547.50 close
Next Story

Tencent stock price: WeChat AI “red packet” fight shadows Monday open after HK$547.50 close

Go toTop